Vetoquinol SA (EPA:VETO)

Market Cap	1.02B +20.3%
Revenue (ttm)	527.34M -0.9%
Net Income	62.83M +4.8%
EPS	5.45 +6.9%
Shares Out	11.62M
PE Ratio	16.10
Forward PE	15.84
Dividend	0.93 (1.06%)
Ex-Dividend Date	Jun 3, 2026

Volume	2,102
Open	86.60
Previous Close	86.50
Day's Range	86.20 - 87.70
52-Week Range	65.70 - 91.50
Beta	0.77
Analysts	Buy
Price Target	92.08 (+4.99%)
Est. Earnings	Mar 22, 2027

About Vetoquinol

Vetoquinol SA, a veterinary pharmaceutical company, engages in designing, developing, and selling of veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA operates as a ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1933
• Employees: 2,526
• Stock Exchange: Euronext Paris
• Ticker Symbol: VETO

Financial Performance

In 2025, Vetoquinol's revenue was 525.69 million, a decrease of -2.51% compared to the previous year's 539.20 million. Earnings were 57.36 million, a decrease of -2.26%.

Analyst Summary

According to 4 analysts, the average rating for VETO stock is "Buy." The 12-month stock price target is €92.08, which is an increase of 4.99% from the latest price.

Price Target

€92.08

(4.99% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 11, 2026

Data Sources Report a data error